Ohe Y, Matsuura M, Nakajima Y, Shin S, Hashimoto F, Hirota M, Shima K
Otsuka Assay Laboratories, Otsuka Pharmaceutical Co. Ltd., Tokushima, Japan.
Clin Chim Acta. 1987 Nov 16;169(2-3):229-38. doi: 10.1016/0009-8981(87)90323-8.
An immunoassay specific for glycosylated albumin was developed by the use of beads coated with antibody to human serum albumin (beads) and 125I-labelled monoclonal antibody to reduced bovine glucosylated low density lipoprotein. One bead was capable of binding 100 ng of serum albumin which had been treated with sodium borohydride (NaBH4) to reduce the Schiff base in the protein. The monoclonal antibody reaction with glucitol-lysine epitopes on the reduced glucosylated proteins and amino acids studied, including human serum albumin (HSA), bovine serum albumin and hippuryl-L-lysine. The detection limit of this assay was 100 pmol/mg HSA, which was sensitive enough for clinical use. The mean serum reduced glycosylated albumin concentration measured by this new method was significantly higher in diabetic patients (2.63 +/- 0.35 nmol/mg HSA, n = 32) than in healthy subjects (0.53 +/- 0.05 nmol/mg HSA, n = 38). The serum reduced glycosylated albumin concentration correlated with both hemoglobin A1c (r = 0.69, p less than 0.005) and the fasting blood glucose level (r = 0.51, p less than 0.005) in diabetic patients.
通过使用包被有抗人血清白蛋白抗体的珠子(微珠)和125I标记的抗还原型牛糖化低密度脂蛋白单克隆抗体,开发了一种针对糖化白蛋白的免疫测定法。一个微珠能够结合100 ng经硼氢化钠(NaBH4)处理以还原蛋白质中席夫碱的血清白蛋白。研究了该单克隆抗体与还原型糖化蛋白上的葡糖醇-赖氨酸表位以及包括人血清白蛋白(HSA)、牛血清白蛋白和马尿酰-L-赖氨酸在内的氨基酸的反应。该测定法的检测限为100 pmol/mg HSA,对临床应用而言灵敏度足够。用这种新方法测得的糖尿病患者血清还原型糖化白蛋白平均浓度(2.63±0.35 nmol/mg HSA,n = 32)显著高于健康受试者(0.53±0.05 nmol/mg HSA,n = 38)。糖尿病患者血清还原型糖化白蛋白浓度与糖化血红蛋白A1c(r = 0.69,p<0.005)和空腹血糖水平(r = 0.51,p<0.005)均相关。